| Ytd | 54.01% | |
| 1y | 78.81% |
| Open | 2.05 | Prev Close | 2.08 | Low | 2.05 | High | 2.18 | Mkt Cap | 728.28M |
| Vol | 12.87M | Avg Vol | 11.25M | EPS | -0.77 | P/E | N/A | Forward P/E | -1.50 |
| Beta | 0.84 | Short Ratio | 11.46 | Inst. Own | 80.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.10 | 200-d Avg | 1.80 | 1yr Est | 9.04 |
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the an
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev
U.S. stocks were mixed on Thursday, with the Dow Jones gaining 0.1%. Aehr Test Systems shares rose 1
Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham rais
HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a
Jefferies analyst Roger Song maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises
US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbir
Study Highlights Dagger Technology Showing that an Optimized CD70 CAR has the Potential to Protect A
Bernstein analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market P
Argus Research analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Mar
Citizens analyst Reni J. Benjamin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Out
US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnin
Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i
Baird analyst Jack Allen maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and rai
HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a
Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced that it intends to offer and sell, in an u
Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to d
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the de
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the de
U.S. stock futures lower, Dow futures down 300 points. Worthington Steel Inc (NYSE: WS) shares fall
Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data.
Piper Sandler analyst Biren Amin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight
U.S. stocks higher as Dow Jones gains 300 points; El Pollo LoCo Holdings jumps 17.6% on better-than-
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.17) per share which beat the an
UBS analyst Michael Yee initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Buy rati
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for it
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on F